Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMELD Study of imeglimin in MASLD with type 2 diabetes
jRCTs051220094Phase 2Active, not recruiting
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imeglimin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM). Primary endpoint: Reduction in ALT after 24-week administration of imeglimin hydrochloride. Started Nov 2022; status: active, not recruiting.
02
Drugs
imeglimin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220094.